Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teniposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 0.61 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | TOP1 | P11387 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teniposide SCHEMBL5324539 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Teniposide SCHEMBL2872864 | 0.95 | SMN1; SMN2 (0.56) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Etoposide SCHEMBL1276328 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Teniposide SCHEMBL1276780 | 0.91 | GAA (0.66) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Teniposide SCHEMBL28858804 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Teniposide SCHEMBL4763786 | 0.89 | GAA (0.49) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Teniposide SCHEMBL8350778 | 0.84 | GAA (0.53) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Etoposide SCHEMBL14931202 | 0.83 | GAA (0.61) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Etoposide SCHEMBL18921683 | 0.83 | GAA (0.61) | SMN1; SMN2GAACYP3A4TOP2ATOP2B | |
| Irinotecan SCHEMBL17102276 | 0.83 | GAA (0.54) | SMN1; SMN2GAACYP3A4TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| EP-1578711-A4 | DITERPENOID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE AS ANTI-CANCER OR ANTI-FUNGAL AGENTS | GEMIN X BIOTECHNOLOGIES INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| EP-1578711-A2 | DITERPENOID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE AS ANTI-CANCER OR ANTI-FUNGAL AGENTS | Gemin X Biotechnologies Inc. (CA) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004052282-A2 | DITERPENOID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE AS ANTI-CANCER OR ANTI-FUNGAL AGENTS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| EP-1427722-A2 | PYRROLE-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER, TREATING VIRAL DISEASES AND CAUSING IMMUNOSUPPRESSION | Gemin X Biotechnologies Inc. (CA) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003008410-A2 | POLYPYRROLES AS AGENTS FOR TREATING CANCER, TREATING VIRAL DISEASES AND CAUSING IMMUNOSUPPRESSION | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TOP2A 1944/4885TOP2B 2167/4885SMN1; SMN2 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.